Klinikum Esslingen GmbH

At Klinikum Esslingen, investigators are focusing on improving outcomes for the most vulnerable newborns. The research examines innovative respiratory support strategies for preterm infants born between 23 and 28 weeks, aiming to reduce complications such as retinopathy of prematurity and bronchopulmonary dysplasia. A parallel effort evaluates the safety of new ventilator algorithms that automatically adjust oxygen delivery.

• Closed‑loop oxygen control versus manual adjustment in extremely low‑birth‑weight infants
• Evaluation of long‑term neurodevelopmental outcomes after novel ventilation
• Assessment of respiratory morbidity in infants receiving automated FiO₂ regulation

The site participates in 74 active trials with a team of 20 investigators, reflecting a strong commitment to neonatal care.

The department of women’s health at Klinikum Esslingen conducts extensive research on cancers that affect women, especially breast cancer and ovarian cancer. Trials test novel antibody‑drug conjugates, immunotherapy combinations, and targeted agents to improve survival after surgery and chemotherapy. Some studies also explore hormonal therapies for hormone‑receptor‑positive disease.

• Neoadjuvant atezolizumab for triple‑negative breast cancer
• Adjuvant HER2‑targeted therapy in early‑stage disease
• PARP inhibitor plus chemotherapy for high‑grade serous ovarian cancer
• Hormone‑free maintenance strategies for ER‑positive breast cancer

Among the 74 trials, a substantial proportion address female urogenital malignancies, supported by 20 dedicated investigators.

Research in the hematology unit of Klinikum Esslingen targets blood‑related malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and various lymphomas. The goal is to identify safer, more effective regimens by combining targeted antibodies, kinase inhibitors, and novel cellular therapies.

• Combination of venetoclax with hypomethylating agents in AML
• BTK inhibitor added to reduced‑dose R‑CHOP for elderly diffuse large B‑cell lymphoma
• CAR‑T cell feasibility in relapsed multiple myeloma
• Novel monoclonal antibodies for chronic lymphocytic leukemia

The site’s portfolio includes multiple trials on hematologic cancers, with 20 investigators contributing to 74 studies overall.

Klinikum Esslingen’s oncology program spans a broad spectrum of solid tumors, from non‑small cell lung cancer to gastrointestinal and biliary cancers. Clinical investigations assess precision‑medicine approaches, including ALK and KRAS inhibitors, as well as immunotherapy‑based combinations, to extend survival and improve quality of life.

• ALK‑positive NSCLC targeted therapy with next‑generation inhibitors
• KRAS G12C inhibitor plus pembrolizumab in KRAS‑mutated lung cancer
• Immunotherapy plus chemotherapy in resectable gastric adenocarcinoma
• Adjuvant durvalumab in early‑stage NSCLC after surgery
• FGFR2‑fusion directed therapy for intrahepatic cholangiocarcinoma

Out of the 74 active trials, many focus on advanced solid tumours, reflecting the site’s multidisciplinary expertise.

The respiratory research at Klinikum Esslingen concentrates on malignant lung conditions, particularly small‑cell lung cancer and various subtypes of non‑small cell lung cancer. Trials evaluate novel checkpoint inhibitors, antibody‑drug conjugates, and targeted agents to overcome resistance and achieve durable responses.

• Checkpoint inhibitor versus chemotherapy in extensive‑stage SCLC
• Maintenance immunotherapy after definitive chemoradiation for stage III NSCLC
• Antibody‑drug conjugate for PD‑L1‑high NSCLC
• Combination of anti‑angiogenic therapy with immunotherapy in metastatic NSCLC
• Biomarker‑driven arms for EGFR and ROS1 alterations

These lung‑focused studies form a core component of the 74 trials conducted at the site, with a dedicated team of investigators.